Louisiana Zofran Lawsuit Plaintiffs Allege Drug Exposure Caused Both Daughters’ Cardiac Malformations

March 29, 2016 – – ZofranLegal.com reports on another lawsuit concerning anti-nausea drug Zofran filed against pharmacetical giant and Zofran manufacturer GlaxoSmithKline by parents from Montegut, Louisiana. The parents allege that the mother’s use of the drug while pregnant with each daughter (and therefore exposure to each daughter within the womb), caused their daughters to be born with cardiac malformations. Court documents state that the daughters were born within a year of each other and both suffer from the development of congenital heart defects. According to their parents, this was due to Zofran exposure while they were in utero.

The family’s lawsuit was initially filed within the U.S. District Court for the Eastern District of Louisiana on March 3rd of 2016, but was then transferred to Boston, Massachusetts to a U.S. District Court in order to join the other complaints consolidated by the U.S. Judicial Panel on Multidistrict Litigation. The lawsuit is filed under case number 1:16-cv-10544-FDS.

Unfortunately, these parents are not alone in their concerning claim. Parents from across the United States have filed Zofran lawsuits and allege strikingly similar complaints concerning the development of birth defects in unborn children exposed to the drug. Lawsuits commonly name the following defects: cleft lip and palate, atrial septal defect and ventricular septal defect, transposition of the greater vessels, clubfoot, kidney defects, and respiratory distress syndrome. Some parents have reported that their children actually passed away due to the severity of their birth defects.

Plaintiffs involved in lawsuits against the drug commonly note the fact that Zofran used as a treatment for morning sickness among pregnant women is considered “off label” use. This means that the drug was never approved by the FDA for this use. Instead, the FDA specifically approved Zofran to treat patients suffering from nausea and vomiting episodes after undergoing chemotherapy, radiation, or anesthesia. Reportedly, however, after this approval, manufacturer GSK went on to market the drug as a safe and effective treatment for morning sickness diagnosed in expectant mothers.

The attorneys at Monheit Law understand the seriousness of this potential risk for unborn children. They are currently working to help mothers who used the drug while pregnant and who later gave birth to children with defects. Affected families, women, and children may be entitled to substantial compensation gained through legal action. The attorneys of Monheit Law are working to ensure that those affected are given the important opportunity to evaluate their legal rights. Patients wishing to look further into their legal options are offered free consultations at this time.

To ask questions or request additional information concerning Zofran birth defect lawsuits, please contact the attorneys of Monheit Law by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60008956